Overview

Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis

Status:
Terminated
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effectiveness of hydrocortisone ophthalmic ointment compared to placebo in the treatment of Allergic Conjunctivitis.
Phase:
Phase 2
Details
Lead Sponsor:
Koffler Vision Group
Collaborators:
Fera Development, LLC
Fera Pharmaceuticals, LLC
Treatments:
Cortisol succinate
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate